Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Pfizer and BioNTech tease next-gen COVID-19 vaccine strategy

By Brian Buntz | July 27, 2022

Pfizer-BioNTechAs federal officials wax poetic about the prospect of intranasal COVID-19 vaccines and other novel vaccine platforms, Pfizer Inc. (NYSE:PFE) and its partner BioNTech (Nasdaq:BNTX) have announced that a randomized Phase 2 study will study an incrementally improved COVID-19 vaccine known as BNT162b5.

The updated vaccine candidate includes a modified spike protein designed to bolster immunogenicity over the first-generation COVID-19 vaccine.

“BNT162b5 is the first of various approaches Pfizer and BioNTech intend to study in the clinic as we explore next-generation COVID-19 vaccines with the ultimate goal of increasing the durability of the immune response, which may lead to better protection,” explained a Pfizer spokesperson over email. 

Pfizer notes that it plans on testing multiple vaccine candidates with the novel spike protein design to offer a more durable and broader immune response against SARS-CoV-2 infections and associated COVID-19.

The companies’ original BNT162b2 vaccine remains one of the most widely used worldwide. In 2021, the vaccine was the best-selling pharmaceutical product, generating $51.1 billion between Pfizer and BioNTech.

The bivalent BNT162b5 vaccine blends RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain and the BA.2 sub-lineage of the omicron variant (BA.2 sublineage). “The enhanced spike protein encoded from the mRNAs in BNT162b5 has been modified with the aim of increasing the magnitude and breadth of antibody neutralization response that could better protect against COVID-19,” a Pfizer spokesperson explained. 

The FDA has recommended including omicron BA.4/5 component for future COVID-19 vaccine booster doses.

In its most recent Phase 2 study, Pfizer will evaluate BNT162b5 in approximately 200 participants between 18 and 55. Participants in the study will have received three prior doses of an authorized COVID-19 vaccine at least 90 days before their first study visit.

The study will administer the vaccine booster candidate as a 30-microgram dose.

PFE shares were down 0.66% to $51.95.


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: BioNTech SE, BNT162b2, BNT162b5, Pfizer
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Axcella
Axcella touts positive results from Phase 2a long COVID study
monkeypox
3 critical monkeypox vaccine questions 
Moderna in the Drug Discovery & Development Pharma 50
Moderna inks deal with US for up to 300M omicron boosters
Vaccine
FDA greenlights 786,000 additional monkeypox vaccine doses

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50